Aadi Bioscience Inc
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa… Read more
Market Cap & Net Worth: Aadi Bioscience Inc (AADI)
Aadi Bioscience Inc (NASDAQ:AADI) has a market capitalization of $94.89 Million ($94.89 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26206 globally and #8884 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aadi Bioscience Inc's stock price $2.05 by its total outstanding shares 46288600 (46.29 Million).
Aadi Bioscience Inc Market Cap History: 2017 to 2025
Aadi Bioscience Inc's market capitalization history from 2017 to 2025. Data shows change from $3.30 Billion to $94.89 Million (-39.15% CAGR).
Index Memberships
Aadi Bioscience Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2249 of 3165 |
Weight: Aadi Bioscience Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aadi Bioscience Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aadi Bioscience Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.62x
Aadi Bioscience Inc's market cap is 5.62 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.18 Billion | $20.16 Million | -$10.40 Million | 58.56x | N/A |
| 2019 | $432.91 Million | $749.00K | -$23.27 Million | 577.99x | N/A |
| 2020 | $680.44 Million | $14.00 Million | -$3.48 Million | 48.60x | N/A |
| 2021 | $1.12 Billion | $1.00 Million | -$110.09 Million | 1117.87x | N/A |
| 2022 | $593.88 Million | $15.22 Million | -$57.01 Million | 39.03x | N/A |
| 2023 | $93.50 Million | $24.35 Million | -$65.77 Million | 3.84x | N/A |
| 2024 | $146.04 Million | $25.98 Million | -$63.69 Million | 5.62x | N/A |
Competitor Companies of AADI by Market Capitalization
Companies near Aadi Bioscience Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Aadi Bioscience Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aadi Bioscience Inc Historical Marketcap From 2017 to 2025
Between 2017 and today, Aadi Bioscience Inc's market cap moved from $3.30 Billion to $ 94.89 Million, with a yearly change of -39.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $94.89 Million | -35.02% |
| 2024 | $146.04 Million | +56.19% |
| 2023 | $93.50 Million | -84.26% |
| 2022 | $593.88 Million | -46.87% |
| 2021 | $1.12 Billion | +64.29% |
| 2020 | $680.44 Million | +57.18% |
| 2019 | $432.91 Million | -63.32% |
| 2018 | $1.18 Billion | -64.21% |
| 2017 | $3.30 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Aadi Bioscience Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $94.89 Million USD |
| MoneyControl | $94.89 Million USD |
| MarketWatch | $94.89 Million USD |
| marketcap.company | $94.89 Million USD |
| Reuters | $94.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.